A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma

Am J Hematol. 2021 Jul 1;96(7):E243-E246. doi: 10.1002/ajh.26178. Epub 2021 May 6.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Bendamustine Hydrochloride / therapeutic use*
  • Dexamethasone / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Neoplasm Recurrence, Local / drug therapy*
  • Oligopeptides / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Oligopeptides
  • carfilzomib
  • Dexamethasone
  • Bendamustine Hydrochloride